isolates from patients later treated with cefazolin. Upon receipt, the isolates were classified and tested for response to 12 commercial antibiotics. A single passage of the organism was made, and samples were frozen at -70 C for additional trials.
tration determinations were conducted on 591 clinical isolates. Cefazolin demonstrated superior activity, as shown by lower minimal inhibitory concentrations, and a greater percentage of isolates inhibited in the disk susceptibility test. The cephalothin antibiotic class disk by the standard Bauer-Kirby method failed to detect susceptibility to cefazolin in a significant percentage of Escherchia coli, Enterobacter species, and Enterococcus isolates. A separate cefazolin disk with a susceptibility cut-off point of 18 mm is recommended. An alternative to a separate cefazolin disk would be a reinterpretation of the cephalothin susceptibility disk zone diameters so that it would more adequately predict cefazolin activity.
Standard regulatory methods for tfie testing of antibiotic disk susceptibility have been published in the Federal Register (3) . Representing the cephalosporin antibiotics is a disk containing 30 ,g of cephalothin. This disk is to be used in the determination of cephalothin, cephaloridine, cephaloglycine, and cephalexin susceptibilities. The use of such a representative, or class, disk assumes that it will cover adequately the susceptibilities within the antibiotic class. Because our laboratory is in the process of developing a new cephalosporin, cefazolin, we decided to undertake studies to compare the 30-,gg cephalothin disk with a 30-/ig cefazolin disk. The primary purpose of these studies was to determine the adequacy of the cephalosporin class disk in predicting cefazolin response as well as to detect potential differences in the two antibiotic disks. A battery of susceptibility tests comparing the two antibiotic disks was performed against a variety of gram-positive and gram-negative clinical bacterial isolates. In addition, the minimal inhibitory concentrations of cefazolin and cephalothin for each isolate were determined in order to correlate these values with the data obtained in the disk susceptibility studies.
MATERIALS AND METHODS Bacterial isolates. Isolates used in these studies were obtained from hospitalized patients and sent to our laboratory from a variety of geographical locations in the United States. These samples included some isolates from patients later treated with cefazolin. Upon receipt, the isolates were classified and tested for response to 12 commercial antibiotics. A single passage of the organism was made, and samples were frozen at -70 C for additional trials.
Antibiotic disks. Cephalothin 30-,ug disks were purchased from BBL. The 30-iAg cefazolin disks were prepared in the BBL laboratories under controlled conditions conforming to their commercial production of susceptibility disks. The disks were assayed for stability over a 1-year period in both BBL and our laboratories and found to have no significant loss in potency when stored at 4 C. The assays were performed by the FDA performance plate test method described in the Federal Register for cephalosporin disks (2).
Disk susceptibility tests. The procedure employed was essentially that of Bauer and Kirby (1) Figure 3 represents a plot of the log MIC for cefazolin plotted against the species average zone diameters for cephalothin. By using the equation given for the regression line, it can be calculated that the zone diameter of 14 mm for cephalothin will, on the average, correspond to a cefazolin MIC of 4.8 ,ug/ml. This MIC represents a concentration which is readily attainable in serum of patients treated with cefazolin, even with a 250-mg dose. Determination of susceptibility of isolates. The results of the Bauer-Kirby disk susceptibility tests are shown in Table 2 , which shows the susceptibility patterns obtained using several parameters of classification for sensitive, intermediate, and resistant. A comparison of the data obtained with the 30-,gg cefazolin and cephalothin disks, by using 18 mm as the susceptibility cut-off point (SCOP), shows a number of significant differences with the various species of clinical isolates. In general, a much higher percentage of the isolates were found to be susceptible to the cefazolin disk. 10 (Table 2 ).
In any event, patients infected with strains of Enterobacter found to be susceptible to cefazolin were found to respond to cefazolin treatment (12, Gold et al., J. Infect. Dis., in press).
The log of the MIC values for cefazolin and cephalothin were plotted against the average zone diameters for each species of clinical isolate studied ( Fig. 1 and 2 ). Only those species VOL. 5, 1974 on June 27, 2017 by guest http://aac.asm.org/ 30-gAg cephalothin and cephacetrile disks. Although cephacetrile consistently gave larger zone diameters in the Bauer-Kirby system, these differences rarely resulted in a change in the susceptibility category of an organism. The cephalothin response (zone diameter measurements) did not predict the cephacetrile response. The responses of individual isolates toward cephaloridine and cephaloglycine also were found to be different. As a result of these findings, we questioned the wisdom of using a single representative of a group of antibiotic agents to measure susceptibility toward all derivatives. A similar conclusion has been expressed by Wick and Preston (13) , who worked with three heterocyclic thiomethyl cephalosporins, including cefazolin. They reasoned that the high serum levels attainable plus the extended activity spectrum argue against a class cephalosporin disk.
An analysis of the available data, to obtain the regression line relating the logarithm of the cephazolin MIC and cephalothin disk diameter, can be used in reinterpreting the cephalothin zone diameter data so that it will predict cefazolin activity (Fig. 3) . Specifically, it appears that the appropriate cephalothin zone diameters for predicting cefazolin susceptibility should be as follows: > 14 mm, susceptible; 11 to 13 It would appear from these studies that the present class cephalosporin (cephalothin) disk fails to predict adequately cefazolin activity, particularly in the case of E. coli and E. aerogenes. In light of the superior serum levels observed in humans with cefazolin (three to four times that of cephalothin) after intramuscular injection and the improved microbiological activity, a separate cefazolin disk would be justified. An alternate approach to the problem would be to reinterpret the cephalothin class susceptibility disk zone sizes so that they adequately predict cefazolin activity.
